12:00 - 1:00pm EST

Future technologies for cell & gene therapy

see more info
1:30 - 2:30pm EST

Pricing & reimbursement: Unlocking the potential for ATMPs

see more info
3:00 - 4:00pm EST

Funding CGTx: 2022 and beyond

see more info
August 24, 12:00 - 1:00pm EST

Future technologies for cell & gene therapy

Advanced therapies have been a significant disruptor in healthcare, fundamentally transforming the way diseases are treated. How are advances specific to technology continuing to drive this innovation forward? Join our panel on cutting-edge technologies, their effectiveness, and what we as a sector must still overcome to bring these treatments to the patient.

In this panel you will learn about:

  • Novel gene therapy delivery systems
  • Innovation in manufacturing
  • Gene editing, iPSCs, and other new technologies
  • Autologous vs. allogenic cell therapies
  • Regulatory hurdles that these new technologies are facing
Fred Cohen
Fred Cohen
Co-founder & Chairman
Monograph Capital Partners
Deborah Phippard
Deborah Phippard
CSO
Precision for Medicine
Palani Palaniappan
Palani Palaniappan
CTO
Pioneering Medicines at Flagship Pioneering
Dave Lennon
Dave Lennon
CEO
Satellite Bio
Robert Ang
Robert Ang
CEO
Vor Bio
Mark McCamish
Mark McCamish
President & CEO
IconOVir Bio
Anshul Mangal
Anshul Mangal
President
Precision Advance & Project Farma
moderator
August 24, 1:30 - 2:30pm EST

Pricing & reimbursement: Unlocking the potential for ATMPs

Pressure is being applied to the ‘traditional’ healthcare reimbursement model. As novel therapies continue to propel towards commercialization, healthcare systems and manufacturers are being asked to embrace evidence-based pricing strategies to lessen the burden of upfront costs. Our panelists will discuss how stakeholders across the drug development continuum can work together to manage availability and affordability, while reducing patient-adverse outcomes for these life-saving treatments.

In this panel you will learn about:

  • The current state of therapy pricing, reimbursement, and value demonstration
  • Solutions for improving patient access
  • How to better understand durability of effect and long-term data requests
  • Shifting from rare to prevalent indications
  • Understanding payer and HTA engagement in the US and EU markets
Phil Cyr
Phil Cyr
Senior Vice President
Precision Value & Health
Brett Kopelan
Brett Kopelan
Executive Director
Debra of America
Janet Lambert
Janet Lambert
CEO
Alliance for Regenerative Medicine (ARM)
Michele Korfin
Michele Korfin
COO & CCO
Gamida Cell Ltd
Ross Maclean
Ross Maclean
EVP
PRECISIONheor (Precision Value & Health)
moderator
August 24, 3:00 - 4:00pm EST

Funding CGTx: 2022 and beyond

The money dump into late-stage drug development came to a screeching halt in 2022. How do investors view the cell & gene landscape and where exactly is it headed? John Carroll and a team of experts will examine this recent downturn and find out what it’ll take to get funding back on track.

Kiran Reddy
Kiran Reddy
Senior Managing Director
Blackstone
Peter Emtage
Peter Emtage
Venture Partner
Versant
Fred Cohen
Fred Cohen
Co-founder & Chairman
Monograph Capital Partners
Janis Naeve
Janis Naeve
Partner
Cota Capital
John Carroll
John Carroll
Editor & Founder
Endpoints News
moderator